Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. | Chief Scientific Officer | 202.94k | -- | -- |
| Dr. Philippe Jacques Wolgen M.B.A., M.D. | CEO, MD & Director (Leave of Absence) | 1.71M | -- | 1963 |
| Mr. Lachlan Hay | COO & Acting CEO | -- | -- | -- |
| Mr. Peter Vaughan | Chief Financial Officer | -- | -- | -- |
| Mr. Malcolm Bull | Head of Australian Operations & Investor Relations | -- | -- | -- |
| Dr. Rose Quadbeck-Diel | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Dr. Azza Hamila | Head of Quality Assurance & Drug Safety | -- | -- | -- |
| Ms. Claire Newstead-Sinclair C.A. | Company Secretary | -- | -- | -- |
Clinuvel Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Corporate Governance
Upcoming Events
February 26, 2025 at 11:48 PM UTC
Clinuvel Pharmaceuticals Limited Earnings Date
Recent Events
September 5, 2024 at 12:00 AM UTC
Ex-Dividend Date